IJE Advance Access originally published online on May 27, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
International Journal of Epidemiology, Volume 33, Number 3, pp. 461-463
IJE vol.33 no.3 © International Epidemiological Association 2004; all rights reserved.
Commentary |
Commentary: Hormone replacement therapy and coronary heart disease: four lessons
Kaiser Permanente Southern California, 393 E Walnut Street, Pasadena, CA 91188, USA. E-mail: diana.b.petitti@kp.org
| The first 150 words of the full text of this article appear below. |
In 1991, Stampfer and Colditz,1 reviewing epidemiological studies of the effect of postmenopausal oestrogen on coronary heart disease concluded that: ‘... the bulk of evidence strongly supports a protective effect of estrogens that is unlikely to be explained by confounding factors ...’
Their best estimate of the relative risk of coronary heart disease (CHD) in postmenopausal oestrogen users was calculated using meta-analytical techniques applied to the epidemiological studies they deemed to be of high quality based on their designs—prospective studies with internal controls and angiographic studies. This estimate was 0.50. The CI was narrow –0.43 to 0.56.
The Stampfer and Colditz paper was cited widely. It became a shorthand citation for the contention that the ‘epidemiologic evidence showing that hormone replacement therapy prevents coronary heart disease is overwhelming.’
In 1998, the results of the first large randomized, placebo-controlled trial of the effect of combined oestrogen/progestin hormone replacement therapy on coronary
 |
Lesson one: do not turn a blind eye to contradiction |
|---|
|
Lesson two: do not be seduced by mechanism |
|---|
|
Lesson three: suspend belief |
|---|
|
Lesson four: maintain scepticism |
|---|
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. S. Linet Invited Commentary: Postmenopausal Unopposed Estrogen and Breast Cancer Risk in the Women's Health Initiative--Before and Beyond Am. J. Epidemiol., June 15, 2008; 167(12): 1416 - 1420. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Krieger Hormone therapy and the rise and perhaps fall of US breast cancer incidence rates: critical reflections Int. J. Epidemiol., June 1, 2008; 37(3): 627 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Paul Commentary: Hormone therapy and breast cancer incidence: did epidemiologists miss an effect on national trends? Int. J. Epidemiol., June 1, 2008; 37(3): 638 - 640. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Macleod Cannabis use and psychosis: the origins and implications of an association Advan. Psychiatr. Treat., November 1, 2007; 13(6): 400 - 411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Anderson, C. Kooperberg, N. Geller, J. E. Rossouw, M. Pettinger, and R. L. Prentice Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials Clinical Trials, June 1, 2007; 4(3): 207 - 217. [Abstract] [PDF]
|
|
|
|
|
|
F. de Vries, C. de Vries, C. Cooper, B. Leufkens, and T.-P. van Staa Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database. Int. J. Epidemiol., October 1, 2006; 35(5): 1301 - 1308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Raven Do enforced bicycle helmet laws improve public health? Evidence is conflicting. BMJ, April 8, 2006; 332(7545): 852 - 852. [Full Text]
|
|
|
|
 |
|
 N. Krieger, I. Lowy, R. Aronowitz, J. Bigby, K. Dickersin, E. Garner, J.-P. Gaudilliere, C. Hinestrosa, R. Hubbard, P. A Johnson, et al. Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical, and advocacy perspectives J. Epidemiol. Community Health, September 1, 2005; 59(9): 740 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Prentice, R. Langer, M. L. Stefanick, B. V. Howard, M. Pettinger, G. Anderson, D. Barad, J. D. Curb, J. Kotchen, L. Kuller, et al. Combined Postmenopausal Hormone Therapy and Cardiovascular Disease: Toward Resolving the Discrepancy between Observational Studies and the Women's Health Initiative Clinical Trial Am. J. Epidemiol., September 1, 2005; 162(5): 404 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S Guzelian, M. S Victoroff, N C. Halmes, R. C James, and C. P Guzelian Evidence-based toxicology: a comprehensive framework for causation Human and Experimental Toxicology, April 1, 2005; 24(4): 161 - 201. [Abstract] [PDF]
|
|
|
|
|
|
E. von Elm and M. Egger The scandal of poor epidemiological research BMJ, October 16, 2004; 329(7471): 868 - 869. [Full Text] [PDF]
|
|
|
|
|
|
G. D. Smith Classics in epidemiology: should they get it right? Int. J. Epidemiol., June 1, 2004; 33(3): 441 - 442. [Full Text] [PDF]
|
|